129 related articles for article (PubMed ID: 37541924)
1. Cannabidiol's impact on drug-metabolization.
Stöllberger C; Finsterer J
Eur J Intern Med; 2023 Dec; 118():6-13. PubMed ID: 37541924
[TBL] [Abstract][Full Text] [Related]
2. The Potential for Pharmacokinetic Interactions Between Cannabis Products and Conventional Medications.
Qian Y; Gurley BJ; Markowitz JS
J Clin Psychopharmacol; 2019; 39(5):462-471. PubMed ID: 31433338
[TBL] [Abstract][Full Text] [Related]
3. Cannabidiol and cannabidiolic acid: Preliminary in vitro evaluation of metabolism and drug-drug interactions involving canine cytochrome P-450, UDP-glucuronosyltransferase, and P-glycoprotein.
Court MH; Mealey KL; Burke NS; Jimenez TP; Zhu Z; Wakshlag JJ
J Vet Pharmacol Ther; 2024 Jan; 47(1):1-13. PubMed ID: 37469115
[TBL] [Abstract][Full Text] [Related]
4. Rhinacanthin-C Mediated Herb-Drug Interactions with Drug Transporters and Phase I Drug-Metabolizing Enzymes.
Dunkoksung W; Vardhanabhuti N; Siripong P; Jianmongkol S
Drug Metab Dispos; 2019 Oct; 47(10):1040-1049. PubMed ID: 31399508
[TBL] [Abstract][Full Text] [Related]
5. Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes.
Jiang R; Yamaori S; Takeda S; Yamamoto I; Watanabe K
Life Sci; 2011 Aug; 89(5-6):165-70. PubMed ID: 21704641
[TBL] [Abstract][Full Text] [Related]
6. Cannabinoid Interactions with Cytochrome P450 Drug Metabolism: a Full-Spectrum Characterization.
Doohan PT; Oldfield LD; Arnold JC; Anderson LL
AAPS J; 2021 Jun; 23(4):91. PubMed ID: 34181150
[TBL] [Abstract][Full Text] [Related]
7. Drug metabolism and drug transport of the 100 most prescribed oral drugs.
Iversen DB; Andersen NE; Dalgård Dunvald AC; Pottegård A; Stage TB
Basic Clin Pharmacol Toxicol; 2022 Nov; 131(5):311-324. PubMed ID: 35972991
[TBL] [Abstract][Full Text] [Related]
8. Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450.
Bansal S; Maharao N; Paine MF; Unadkat JD
Drug Metab Dispos; 2020 Oct; 48(10):1008-1017. PubMed ID: 32587099
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of drug interaction potential of zanubrutinib with cocktail probes representative of CYP3A4, CYP2C9, CYP2C19, P-gp and BCRP.
Ou YC; Tang Z; Novotny W; Tawashi M; Li TK; Coleman HA; Sahasranaman S
Br J Clin Pharmacol; 2021 Jul; 87(7):2926-2936. PubMed ID: 33336408
[TBL] [Abstract][Full Text] [Related]
10. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review.
Stout SM; Cimino NM
Drug Metab Rev; 2014 Feb; 46(1):86-95. PubMed ID: 24160757
[TBL] [Abstract][Full Text] [Related]
11. Potential Determinants for Metabolic Fates and Inhibitory Effects of Isobavachalcone Involving in Human Cytochrome P450, UDP-Glucuronosyltransferase Enzymes, and Efflux Transporters.
Qin Z; Wang P; Duan S; Wan X; Xing H; Yang J; Zhang X; Yao Z; Yao X
J Pharm Sci; 2021 May; 110(5):2285-2294. PubMed ID: 33610566
[TBL] [Abstract][Full Text] [Related]
12. Napabucasin Drug-Drug Interaction Potential, Safety, Tolerability, and Pharmacokinetics Following Oral Dosing in Healthy Adult Volunteers.
Dai X; Karol MD; Hitron M; Hard ML; Goulet MT; McLaughlin CF; Brantley SJ
Clin Pharmacol Drug Dev; 2021 Aug; 10(8):824-839. PubMed ID: 34107166
[TBL] [Abstract][Full Text] [Related]
13. Traditional Herbal Formulas to as Treatments for Musculoskeletal Disorders: Their Inhibitory Effects on the Activities of Human Microsomal Cytochrome P450s and UDP-glucuronosyltransferases.
Jin SE; Seo CS; Shin HK; Ha H
Pharmacogn Mag; 2016; 12(48):241-252. PubMed ID: 27867264
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacogenetics and potential application in personalized medicine.
Zhou SF; Di YM; Chan E; Du YM; Chow VD; Xue CC; Lai X; Wang JC; Li CG; Tian M; Duan W
Curr Drug Metab; 2008 Oct; 9(8):738-84. PubMed ID: 18855611
[TBL] [Abstract][Full Text] [Related]
15. Modulation of Cytochrome P450, P-glycoprotein and Pregnane X Receptor by Selected Antimalarial Herbs-Implication for Herb-Drug Interaction.
Fasinu PS; Manda VK; Dale OR; Egiebor NO; Walker LA; Khan SI
Molecules; 2017 Nov; 22(12):. PubMed ID: 29168799
[TBL] [Abstract][Full Text] [Related]
16. In Vitro Interaction of AB-FUBINACA with Human Cytochrome P450, UDP-Glucuronosyltransferase Enzymes and Drug Transporters.
Kim S; Kim DK; Shin Y; Jeon JH; Song IS; Lee HS
Molecules; 2020 Oct; 25(19):. PubMed ID: 33050066
[TBL] [Abstract][Full Text] [Related]
17. Verifying in vitro-determined enzyme contributions to cannabidiol clearance for exposure predictions in human through physiologically-based pharmacokinetic modeling.
Yeung CHT; Beers JL; Jackson KD; Edginton AN
CPT Pharmacometrics Syst Pharmacol; 2023 Mar; 12(3):320-332. PubMed ID: 36540909
[TBL] [Abstract][Full Text] [Related]
18. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.
Reese MJ; Savina PM; Generaux GT; Tracey H; Humphreys JE; Kanaoka E; Webster LO; Harmon KA; Clarke JD; Polli JW
Drug Metab Dispos; 2013 Feb; 41(2):353-61. PubMed ID: 23132334
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Herb-Drug Interaction of Synacinn™ and Individual Biomarker through Cytochrome 450 Inhibition Assay.
Ab Rahman NS; Abd Majid FA; Abd Wahid ME; Zainudin AN; Zainol SN; Ismail HF; Wong TS; Tiwari NK; Giri S; Bhargava V
Drug Metab Lett; 2018; 12(1):62-67. PubMed ID: 29542427
[TBL] [Abstract][Full Text] [Related]
20. In Vitro Assessment of the Drug-Drug Interaction Potential of Verinurad and Its Metabolites as Substrates and Inhibitors of Metabolizing Enzymes and Drug Transporters.
Gopaul VS; Vildhede A; Andersson TB; Erlandsson F; Lee CA; Johansson S; Hilgendorf C
J Pharmacol Exp Ther; 2021 Aug; 378(2):108-123. PubMed ID: 34074714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
